ProCE Banner Activity

The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

Podcast Episodes
In this podcast episode, listen to Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, as they discuss clinical implications of the latest data from ASCO 2021 on using androgen receptor–directed therapy for the treatment and management of patients with nonmetastatic castration-resistant prostate cancer.

Released: July 30, 2021

Expiration: July 29, 2022

No longer available for credit.

Share

Faculty

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Alicia K. Morgans

Alicia K. Morgans, MD, MPH

Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Supporters

Supported by an educational grant from

Bayer HealthCare

Faculty Disclosure

Primary Author

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Karim Fizazi, MD, PhD, has disclosed that he has received consulting fees from AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, CureVac, ESSA, Genentch, Janssen, MSD, Orion, and Sanofi.

Alicia K. Morgans, MD, MPH

Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Alicia K. Morgans, MD, PhD, has disclosed that she has received funds for research support from Bayer, Dendreon, Myovant, Sanofi, and Seattle Genetics and consulting fees from AAA, AstraZeneca, Astellas, Bayer, Blue Earth, Clovis, Dendreon, Exelixis, Janssen, Myovant, Myriad, Novartis, Pfizer, Sanofi and Seattle Genetics.